erf

Larry Schutts
- http://www.stockwinners.com

Larry Schutts, a former university professor, is vice president of Stockwinners.com and a contributing editor for Theflyonthewall.com. Larry looks for stocks with technical and fundamental characteristics indicating gains in the next 30 days. However, price movements may be volatile. He includes a stop-loss price in each post. Consider selling a position should the stop-loss be violated.

Fuqi International (NASDAQ: FUQI) designs, develops and sells precious metal jewelry in the People's Republic of China. It offers rings, bracelets, necklaces, earrings and pendants made from such precious metals as platinum, gold, palladium and karat gold. The company also manufactures jewelry with diamonds and other precious stone inlays, as well as gold coins and gold bars. Fuqi International was founded in 2001 and is headquartered in Shenzhen.

The firm surprised the Street last week, when it reported Q2 EPS of 25 cents and revenues of $66.9 million. The Street had been looking for 20 cents and $62.8 million. Management also guided Q3 EPS to 26-27 cents (21 cent Street), Q3 revenues to $75-$77 million ($70.6M Street), FY08 EPS to $1.07-$1.09 ($1.08 Street) and FY08 revenues to $325-$333 million ($314.2M Street).

BWAY Holding Company (NYSE: BWY), headquartered in Atlanta, is a leading North American manufacturer and distributor of metal and rigid plastic containers for the industrial and consumer products markets. The Metal Packaging segment specializes in steel paint cans, aerosol cans, pails and ammunition boxes. The Plastics Packaging unit provides injection-molded and blow-molded bottles and drums for petroleum products, agricultural chemicals, paints, inks, edible oils, adhesives and sealants. The ICL Industrial Containers division is Canada's leading supplier of plastic and steel pails. Ball Corporation (NYSE: BLL) and Crown Holdings (NYSE: CCK) are major competitors.

The firm surprised the Street last week, when it reported fiscal Q3 EPS of 41 cents and revenues of $274 million. Analysts had been looking for 28 cents and $271.6 million. In discussing the successful quarter, the CEO noted increased productivity, better cost containment and the effects of new products. Management also guided FY08 EPS to 70-75 cents, versus Street consensus of 53 cents.

LDK Solar Company (NYSE: LDK) is a leading manufacturer of the multicrystalline solar wafers used to produce solar cells and modules. The firm provides its wafers, as well as wafer processing services, to major manufacturers of photovoltaic products. More than two-thirds of its revenues derive from sales to companies in the Asia/Pacific region, primarily China and Taiwan.

The company pleased investors on Monday, when it reported Q2 EPS of $1.29 and revenues of $441.7 million. Analysts had been expecting 42 cents and $282 million. Management also guided Q3 revenues to $486-$496 million ($307.05M consensus) and FY08 revenues to $1.65-$1.75 billion ($1.16B consensus). The CEO noted that the firm had signed nine long-term wafer supply agreements year-to-date, further diversifying its customer base. On Wednesday, he announced yet another such agreement, with India-based XL Telecom & Energy.

Astronics Corporation (NASDAQ: ATRO) designs and manufactures electrical power and lighting systems for the aerospace industry. Products generate electricity for aircraft cabins and airframes and provide both interior and external lighting. Customers include manufacturers of business jets, military aircraft, missiles and commercial transports. The company's control panels are also used in a variety of military ground vehicles. Boeing (NYSE: BA), Lockheed Martin (NYSE: LMT) and United Technologies (NYSE: UTX) are among the firm's major clients. Astronics ranked first on the Fortune Small Business Magazine 2008 list of America's 100 fastest-growing small public companies.

The firm surprised the Street earlier in the month, when it reported Q2 EPS of 60 cents and revenues of $47.9 million. Analysts had been looking for 31 cents and $42.1 million. Management also guided FY08 revenues to $175-$185 million, versus Street consensus of $169.49 million. The CEO commented, "While we set an all-time record for shipments in the quarter, the level of orders received was even stronger." Boenning & Scattergood subsequently reiterated its "market outperform" rating on the shares and boosted its price target to $30.

AngioDynamics (NASDAQ: ANGO) provides medical devices used by interventional radiologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. The firm's oncology product line includes image-guided radiofrequency ablation devices, used to kill cancer cells by heating and destroying them. The peripheral vascular line includes a variety of instruments to clear and drain non-cardiac arteries. The company's products are sold in more than thirty countries. Competitors include Johnson & Johnson (NYSE: JNJ) and Boston Scientific (NYSE: BSX).

The firm pleased investors late last month, when it reported fiscal Q4 EPS of 41 cents and revenues of $46.8 million. Analysts had been looking for 17 cents and $45.6 million. Management also guided FY09 EPS to 68 cents (64 cent consensus) and FY09 revenues to $205-$210 million ($201.32M consensus).

Albany Molecular Research (NASDAQ: AMRI) provides contract services to pharmaceutical and biotechnology companies. The firm offers drug discovery, screening programs, libraries for screening and hit-to-lead programs, and analytical quantification of drugs and metabolites in biological samples. The company also conducts its own research, aiming to license its compounds to other firms for further development. Albany Molecular owns a patent for fexofenadine HCl, the key ingredient in Sanofi-Aventis' (NYSE: SNY) antihistamine Allegra.

The company pleased investors last week, when it reported Q2 EPS of 24 cents and revenues of $57.9 million. Analysts had been looking for ten cents and $51.8 million. The CEO noted that submission of a Canadian Clinical Trial Application by partner Bristol-Myers Squibb (NYSE: BMY) triggered a milestone payment to Albany that reflected well on the value of the company's strategic technology platform. Management also guided Q3 EPS to 8-10 cents (seven cent consensus) and FY08 EPS to 48-52 cents (38 cent consensus).

Motorola (NYSE: MOT) provides technologies, products, and services for mobile and home communications. The company's Mobile Devices division offers wireless handsets, with integrated software and accessories. The Home and Networks Mobility segment makes set-top boxes, digital video recorders, cable modems, and network equipment used in video broadcasting, computer telephony, and high-definition television. The Enterprise Mobility unit provides radio, voice and data communication products for a range of enterprise markets. Nokia (NYSE: NOK) and Ericsson (NASDAQ: ERIC) are major competitors.

The firm pleased investors late last month, when it reported Q2 EPS of two cents and revenues of $8.08 billion. Analysts had been expecting a loss of three cents and $7.69 billion. The company had positive operating cash flow of $204 million and ended the quarter with a net cash position of $3.6 billion and a total cash position of $7.8 billion. Management also guided Q3 EPS to 0-2 cents (one cent consensus) and FY08 EPS to 6-8 cents (one cent consensus).

LSI Corporation (NYSE: LSI) designs, develops and markets semiconductors used by original equipment manufacturers in the data networking and consumer electronics markets. It also provides a wide variety of storage systems, sub-assemblies, and storage management software applications. Top clients include Hewlett-Packard (NYSE: HPQ), IBM (NYSE: IBM) and Sony (NYSE: SNE).

The firm surprised the Street late last month, when it reported Q2 EPS of 13 cents and revenues of $692 million. Analysts had been looking for nine cents and $665.5 million. Management also guided Q3 EPS to 11-15 cents (11 cent consensus) and Q3 revenues to $695-$725 million ($693.41M consensus). The CEO noted that the company had recently secured silicon design wins with top-tier hard drive and server makers.

Barrett Business Services (NASDAQ: BBSI) provides a range of human resource management services to small and medium-sized U.S. businesses. The company offers both temporary and long-term staffing to some 2,300 clients, focusing on light industrial, clerical, and technical specialties. It also outsources such human resource services as payroll management, benefits administration and recruiting to about 1,200 clients. Barrett operates primarily on the coasts, through a total of 45 offices.

The company pleased investors last week, when it reported Q2 EPS of 29 cents and revenues of $269.4 million. Analysts had been expecting 22 cents and $264.2 million. Management also guided Q3 EPS to 34-36 cents (28 cent consensus) and Q3 revenues to $277-$282 million ($269.32M consensus). Roth Capital subsequently upgraded BBSI to "buy" status.

Tyco International (NYSE: TYC) is a leading provider of security products and services, fire protection and detection products and services, valves and controls, and other industrial products. The firm has operations in more than 60 countries, employing 118,000 worldwide. Customers include commercial and shipping enterprises, governmental entities, military forces, transportation systems, original equipment manufacturers, engineering contractors and homeowners. General Electric (NYSE: GE) and Honeywell International (NYSE: HON) are major competitors.

The company pleased investors last week, when it reported Q3 EPS of 88 cents and revenues of $5.21 billion. Analysts had been expecting 67 cents and $5.15 billion. Each of the firm's five divisions posted double-digit increases in operating income. Management also guided FY08 EPS to $2.97-$2.99 ($2.76 consensus).

Amgen (NASDAQ: AMGN) is a biotechnology firm engaged in the discovery and manufacture of human therapeutics. It markets products in the areas of supportive cancer care, nephrology, inflammation, and metabolic diseases. Principal offerings include anemia treatments Aranesp and Epogen, rheumatoid arthritis drug Enbrel, and white blood cell stimulator Neupogen. Amgen has marketing alliances with Hoffmann-La Roche and Kirin. Baxter International (NYSE: BAX), Johnson & Johnson (NYSE: JNJ) and Novartis (NYSE: NVS) and major competitors.

The company pleased the Street late last month, when it announced Phase 3 trial results showing that its experimental osteoporosis drug significantly reduced the risk of bone fractures in post-menopausal women. As well, the firm reported Q2 EPS of $1.14 and revenues of $3.76 billion. Both measures topped consensus Street estimates ($1.02, $3.58 billion). Management also guided FY08 EPS to $4.25-$4.45 ($4.19 consensus) and FY08 revenues to $14.6-$14.9 billion ($14.42B consensus). Eight brokerages subsequently declared AMGN a "buy" and issued price targets in the range $67-$80.

RadiSys Corporation (NASDAQ: RSYS) makes system products for embedded computer applications used in the manufacturing automation, medical, transportation, telecommunications, gaming and test equipment markets. Products include embedded boards, board-level modules and chip-level components. The company also offers system integration and repair services. Clients include Nokia (NYSE: NOK), Nortel Networks (NYSE: NT) and IBM (NYSE: IBM).

The firm pleased investors last week, when it reported Q2 EPS of 14 cents and revenues of $97.6 million. Analysts had been expecting six cents and $87.8 million. The CEO attributed success to strong demand for the company's wireless and IP media server products. Management also guided Q3 EPS to 16-22 cents (nine cent consensus) and Q3 revenues to $98-$103 million ($91.2M consensus).

Varian Medical Systems (NYSE: VAR) manufactures medical devices for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. The company also provides X-ray detectors for industrial/security applications and software for managing radiotherapy centers. The firm has manufacturing sites in North America, Europe and China and operates some 60 sales/support offices around the world.

Varian pleased investors last week, when it reported Q3 EPS of 58 cents and revenues of $513 million. Analysts had been looking for 46 cents and $480.3 million. The CEO noted that faster than expected acceptance of Varian's oncology products was a major factor leading to the successful quarter. Management also guided FY08 EPS to about $2.23 ($2.11 consensus) and FY08 revenues to about $2.08-$2.096 billion ($2.05B consensus). Needham and Lazard Capital subsequently reiterated "buy" ratings on the shares.

Charles Schwab Corporation (NASDAQ: SCHW) is a leading provider of financial services, with more than 300 offices, 7.3 million client brokerage accounts, 1.3 million corporate retirement plan participants, 355,000 banking accounts, and $1.4 trillion in client assets. The company provides a full range of securities brokerage, money management and financial advisory services to individual investors and independent investment advisors. The Charles Schwab Bank provides banking and mortgage services. President and COO Walter Bettinger took the CEO reins from founder Charles Schwab this week. Schwab remains executive chairman.

Last week, the company presented its Q2 report. Earnings of 27 cents per share and revenues of $1.31 billion topped Street estimates 26 cents per share and $1.30 billion. Clients brought $26 billion in net new assets to the firm. Active brokerage accounts and retirement plan participants were up 5% and 13% from year-earlier levels and banking accounts more than doubled.

Tempur-Pedic International (NYSE: TPX) makes bedding products. Offerings include pillows, mattresses, adjustable beds and cushions. The goods feature a visco-elastic foam technology that was developed by NASA during the 1970s, to help cushion astronauts during liftoff. The company markets its products through furniture and department stores, medical retailers, hospitals and the Internet. They are sold under the brand names TEMPUR and Tempur-Pedic. About a third of Tempur-Pedic's revenue comes from international sales.

The company pleased investors last week, when it reported Q2 EPS of 27 cents and revenues of $238.7 million. Analysts had been looking for 23 cents and $232.9 million. Over the course of the quarter, the firm increased its cash balance by 46.8% and reduced total debt by 6.8%. Management also issued in-line guidance for FY08 results.